NASDAQ:ALNY

Alnylam Pharmaceuticals Stock Forecast, Price & News

$136.47
-1.76 (-1.27 %)
(As of 04/12/2021 11:59 AM ET)
Add
Compare
Today's Range
$134.31
Now: $136.47
$137.63
50-Day Range
$133.80
MA: $143.34
$155.06
52-Week Range
$114.30
Now: $136.47
$178.41
Volume4,865 shs
Average Volume688,915 shs
Market Capitalization$16.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200
Employees1,453
Year Founded2002

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$219.75 million
Book Value$12.90 per share

Profitability

Net Income$-886,120,000.00
Net Margins-222.19%

Miscellaneous

Market Cap$16.01 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

Is ALNY Stock A Buy or Sell?
March 29, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

179th out of 2,011 stocks

Pharmaceutical Preparations Industry

75th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$136.47
-1.76 (-1.27 %)
(As of 04/12/2021 11:59 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

Is Alnylam Pharmaceuticals a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alnylam Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALNY, but not buy additional shares or sell existing shares.
View analyst ratings for Alnylam Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Alnylam Pharmaceuticals?

Wall Street analysts have given Alnylam Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alnylam Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Alnylam Pharmaceuticals
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Wednesday, February, 10th. The biopharmaceutical company reported ($2.09) EPS for the quarter, missing the Zacks' consensus estimate of ($1.76) by $0.33. The biopharmaceutical company had revenue of $163.56 million for the quarter, compared to the consensus estimate of $142.49 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 65.96% and a negative net margin of 222.19%. During the same period last year, the business earned ($2.47) earnings per share.
View Alnylam Pharmaceuticals' earnings history
.

How has Alnylam Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY stock has increased by 34.0% and is now trading at $136.55.
View which stocks have been most impacted by COVID-19
.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2021 Pre-Market earnings guidance on Thursday, February, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $760-860 million, compared to the consensus revenue estimate of $796.86 million.

What price target have analysts set for ALNY?

19 brokers have issued 1-year price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $74.00 to $235.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $163.42 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price.
View analysts' price targets for Alnylam Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:
  • Dr. John M. Maraganore, CEO & Exec. Director (Age 58, Pay $1.79M)
  • Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA, Pres & COO (Age 58, Pay $1.14M)
  • Mr. Jeffrey V. Poulton, Chief Financial Officer (Age 53, Pay $681.75k)
  • Dr. Akshay K. Vaishnaw, Pres of R&D (Age 58, Pay $986.1k)
  • Dr. Alfred W. Boyle Ph.D., Chief Technical Operations & Quality Officer
  • Dr. Kevin Fitzgerald, Sr. VP & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom, Sr. VP of Investor Relations & Corp. Communications
  • Ms. Laurie Bartlett Keating J.D., Exec. VP, Chief Legal Officer & Sec. (Age 67)
  • Ms. Agnieszka Gallagher, Chief Ethics & Compliance Officer
  • Mr. Mark Baglin, VP of Global Marketing

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Alnylam Pharmaceuticals' key competitors?

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.03%), EFG Asset Management Americas Corp. (0.02%), Foundations Investment Advisors LLC (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals
.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Pacer Advisors Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was bought by a variety of institutional investors in the last quarter, including Foundations Investment Advisors LLC, and EFG Asset Management Americas Corp..
View insider buying and selling activity for Alnylam Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $136.55.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals has a market capitalization of $16.02 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals employs 1,453 workers across the globe.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Where are Alnylam Pharmaceuticals' headquarters?

Alnylam Pharmaceuticals is headquartered at 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.